MS Medical Grand Rounds: Treatment challenges across borders is a discussion-based meeting of one hour duration that uses a patient case study format, similar to a hospital grand rounds meeting. The meeting will focus on region-specific challenges, and the influence of risk factors in MS management.

PROGRAM

TimeSessionChair(s)/Speaker(s)
20:00-20:05Welcome and Introduction
20:05-21:00Case DiscussionsPanelists: B.Yamout (AE) - Chair, M. Alkhawajah (SA), G. Giovannoni (UK), J. Oh (CA), M. Zakaria (EG)

FACULTY

Yamout

Prof. Bassem I. Yamout - Chair
Neurology Institute Director
Harley Street Medical Centre
Abu Dhabi, United Arab Emirates

Mona

Dr. Mona Alkhawajah
Consultant Neurologist
King Faisal Specialist Hospital and Research Center
Riyadh, Saudi Arabia

Gavin

Prof. Gavin Giovannoni
Professor of Neurology
Blizard Institute, Barts and the London School of Medicine and Dentistry
London, United Kingdom

Jiwon

Prof. Jiwon Oh
Medical Director, Barlo MS Centre, St. Michael's Hospital
Associate Professor of Medicine, University of Toronto
Toronto, Canada

Magd

Prof. Magd Zakaria
Professor of Neurology
Ain Shams University
Cairo, Egypt

ASK A QUESTION

If you have a question for the speakers, relating to region-specific challenges or the influence of risk factors in MS management, please submit via the link below.

Deadline: November 9, 2022

TARGET AUDIENCE

  • Specialists
  • Neurologists
  • Practitioners
  • Researchers in the field of MS

REGISTRATION

Registration is complimentary. The MS Medical Grand Rounds content is developed for use outside of the US and is intended for non-US HCPs.

This Medical program is funded and organized by Merck. The materials shown are intended for discussion purposes and must not be considered medical advice from a healthcare professional. It is not intended to promote the use of any products. This program is intended for healthcare professionals only but not for US healthcare professionals. Scientific opinions presented therein do not necessarily represent the position of Merck. Treatment decisions are made on an individual basis by the responsible physician and do not necessarily reflect the position of Merck.